Abstract: Assays and methods for diagnosing and treating autoimmune diseases. Particularly, the invention provides methods for differential diagnosis of specific autoimmune diseases, including autoimmune rheumatic disorders.
Type:
Grant
Filed:
September 29, 2022
Date of Patent:
July 16, 2024
Assignee:
YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventors:
Rachel Sorek, Keren Jakobi-Brook, Pennina Safer, Irun R Cohen
Abstract: Disclosed herein are 3, 4-didehydro- and 3?-deoxy-3, 4-didehydro-compounds, and pharmaceutical compositions thereof. The 3, 4-didehydro- and 3?-deoxy-3, 4-didehydro-compounds, and pharmaceutical compositions thereof may be used in methods of treating diseases including virus-induced diseases, cancer, autoimmune diseases, immune disorders, and bacterial-associated diseases or infections, or combinations thereof. Examples of viral-induced diseases include viral infections by RNA or DNA viruses, for example SARS-CoV-2, EBV, and BKV.
Type:
Application
Filed:
April 14, 2022
Publication date:
July 11, 2024
Applicant:
YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventors:
David SPERANDIO, Helena SHOMAR MONNGES, Eugene J. EISENBERG, Arthur MACHLENKIN
Abstract: This invention provides a process for the preparation of aluminum scandium nitride films. This invention further provides Caluminum scandium nitride films and layers, and devices and systems comprising aluminum scandium nitride films.
Type:
Application
Filed:
May 12, 2022
Publication date:
July 11, 2024
Applicant:
YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventors:
Igor LUBOMIRSKY, David EHRE, Asaf COHEN
Abstract: A microorganism which is genetically modified so that it produces a first essential biomass precursor by metabolizing CO2 using a recombinant carbon fixation enzyme is disclosed. The microorganism produces a second biomass precursor by metabolizing an organic carbon source and not by metabolizing CO2. The microorganism does not use the organic carbon source for producing the first essential biomass precursor.
Type:
Grant
Filed:
March 25, 2019
Date of Patent:
July 9, 2024
Assignee:
Yeda Research and Development Co. Ltd.
Inventors:
Ron Milo, Niv Antonovsky, Elad Noor, Arren Bar-Even, Yehudit Zohar, Lior Zelcbuch, Shmuel Gleizer, Shira Amram
Abstract: A quantum computing system includes a first resonator couplable to a first alkali atom, a second resonator couplable to a second alkali atom, and lasers for trapping, cooling, and manipulating the first alkali atom and the second alkali atom. Detectors detect a presence of the trapped first alkali atom and the trapped second alkali atom, and a processor is configured to receive at least one input signal from at least one of the detectors, the input signal indicating a presence of the trapped first alkali atom and the trapped second alkali atom, and, based on the received input, control at least some of the lasers to manipulate at least one of the trapped first alkali atom and the trapped second alkali atom to thereby generate photonic qubits using the trapped first alkali atom or generate entanglement between photonic qubits transmitted to the trapped second alkali atom.
Type:
Grant
Filed:
October 10, 2023
Date of Patent:
June 25, 2024
Assignees:
Yeda Research and Development Co. Ltd., Quantum Source Labs Ltd.
Inventors:
Gil Semo, Ziv Aqua, Oded Melamed, Dan Charash, Serge Rosenblum, Barak Dayan
Abstract: Provided herein noncovalent hybrids comprising carbon nanotubes (CNTs) and aromatic compounds, composites based on them, process of preparation and uses thereof, e.g. as electrodes and in lithium-ion cells; wherein the hybrids possess superior mechanical and electrical properties.
Type:
Application
Filed:
February 18, 2024
Publication date:
June 20, 2024
Applicant:
YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventors:
Boris RYBTCHINSKI, Aayan MAITY, Haim WEISSMAN, Michal LESKES
Abstract: A method of treating colorectal cancer (CRC) is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of a Mitogen/extracellular signal-regulated kinase (MEK) inhibitor and a SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase (SRC) inhibitor, wherein cancer cells of the subject express an amount of SRC p419 above a predetermined level and do not express a KRAS G12 mutation, thereby treating the CRC.
Type:
Application
Filed:
February 28, 2024
Publication date:
June 20, 2024
Applicants:
Yeda Research and Development Co. Ltd., The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center
Abstract: A method of treating cancer in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of a population of T cells, wherein an alpha chain of a TCR of at least 10% of the T cells of the population has a CDR3 amino acid sequence as set forth in SEQ ID NO: 6, and a beta chain of the CDR has a CDR3 amino acid sequence as set forth in SEQ ID NO: 7.
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
Type:
Application
Filed:
December 11, 2023
Publication date:
June 6, 2024
Applicant:
Yeda Research and Development Co. Ltd.
Inventors:
Michal Eisenbach-Schwartz, Kuti Baruch, Neta Rosenzweig
Abstract: Monoclonal antibodies for the treatment of ovarian cancer are provided also provide are uses of same. Such uses include characterizing the tumor, diagnosing it and treatment of same.
Type:
Application
Filed:
February 2, 2024
Publication date:
May 23, 2024
Applicant:
Yeda Research and Development Co. Ltd.
Inventors:
Irit SAGI, Roei David MAZOR, Ziv SHULMAN
Abstract: The present invention provides a stirring-free scalable electrochemical reactor enabled by alternating current and uses thereof in a method of performing electrosynthesis of organic reaction.
Abstract: Formulations (e.g., solutions) comprising one or more water-soluble polymer(s), liposomes, and an aqueous carrier, are provided. The provided solutions are useful for rinsing, and/or immersing therein, a contact lens and/or in the treatment of ocular discomfort, for example, an ocular discomfort associated with a contact lens. Also provided are kits comprising the solution and a contact lens; articles-of-manufacturing comprising the solution and configured for dispending the solution; and methods utilizing the solution.
Type:
Application
Filed:
January 29, 2024
Publication date:
May 23, 2024
Applicant:
Yeda Research and Development Co. Ltd.
Inventors:
Jacob KLEIN, Ronit GOLDBERG, Jasmine SEROR
Abstract: A method of treating a malignant disease involving T cell exhaustion in a subject, with the proviso that said malignant disease is not a B cell malignancy, is disclosed. The method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84, thereby treating the malignant disease involving the T cell exhaustion. Also disclosed is a method of treating an autoimmune or inflammatory disease in a subject, the method comprising administering to a subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84. A method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of SLAMF1, with the proviso that said agent is not an agent capable of decreasing an activity or expression of CD84, is also disclosed.
Type:
Grant
Filed:
November 5, 2020
Date of Patent:
May 21, 2024
Assignee:
Yeda Research and Development Co. Ltd.
Inventors:
Idit Shachar, Hadas Lewinsky, Lihi Radomir, Anna Wiener
Abstract: A method of treating cancer in a subject in need thereof is disclosed wherein cancer cells of the subject express an EGFR having a mutation in a kinase domain of the receptor. The method comprises administering to the subject a therapeutically effective amount of: (i) an anti-epidermal growth factor receptor (anti-EGFR) antibody; (ii) an AXL inhibitor, and optionally (iii) a tyrosine kinase inhibitor (TKI). Also disclosed is a new anti-AXL antibody.
Abstract: A quantum computing system, method and computer readable storage medium involve tuning a whispering-gallery mode optical resonator to support a resonance frequency associated with a transition frequency of an atom. Operation of a laser is controlled to cause the atom to be trapped adjacent the optical resonator and within the evanescent field portion. Based on an atom presence signal from an optical atom presence detector, an indication is provided that the atom is trapped adjacent the optical resonator. A frequency of a cooling laser is controlled to cool the atom, and the optical resonator is configured to define a closed loop-like mode including an evanescent field portion. The trapping laser is configured to cause the atom to be trapped adjacent the whispering-gallery mode resonator, and the cooling laser is configured to manipulate a state of the atom to thereby cool the atom.
Type:
Grant
Filed:
April 14, 2023
Date of Patent:
May 14, 2024
Assignees:
Yeda Research and Development Co. Ltd., Quantum Source Labs Ltd.
Inventors:
Gil Semo, Ziv Aqua, Oded Melamed, Dan Charash, Serge Rosenblum, Barak Dayan
Abstract: A system for photon correlation of an illuminated object and/or a light source is provided. The system includes a light source for illuminating the object and an optical system having an object-facing side configured to face the object or the light source and a projection side with the projection side having a focal plane. The system also includes a single-chip single photon avalanche photodiode (SPAD) array arranged at the focal plane and a timing circuit associated with the single-chip SPAD array for measuring arrival times of photons detected by the single-chip SPAD array.
Type:
Grant
Filed:
February 28, 2020
Date of Patent:
May 14, 2024
Assignees:
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL), YEDA RESEARCH & DEVELOPMENT CO. LTD.
Inventors:
Ivan Michel Antolovic, Claudio Bruschini, Edoardo Charbon, Gur Lubin, Ron Tenne, Dan Oron, Uri Rossman
Abstract: An isolated cell having a central memory T-lymphocyte (Tcm) phenotype, the cell being tolerance-inducing cell and capable of homing to the lymph nodes following transplantation, the cell being transduced to express a cell surface receptor comprising a T cell receptor signaling module is disclosed. Methods of generating same and using same are also disclosed.
Abstract: A quantum computing system comprises a plurality of photonic cavities, a plurality of coupling locations for quantum emitter positioning, a photon generator configured to supply photons to the plurality of photonic cavities, and a plurality of photon output channels downstream of the plurality of cavities to output a graph state. Each coupling location is associated with a differing one of the plurality of photonic cavities. Quantum emitters associated with each coupling location are configured to mediate interactions between consecutive incoming photonic qubits to generate the graph state, and the photonic cavities are configured to couple photonic qubits to the quantum emitters.
Type:
Grant
Filed:
April 13, 2023
Date of Patent:
May 7, 2024
Assignees:
Yeda Research and Development Co. Ltd., Quantum Source Labs Ltd.
Inventors:
Gil Semo, Ziv Aqua, Oded Melamed, Dan Charash, Serge Rosenblum, Barak Dayan
Abstract: A method of isolating an antibody is disclosed. The method comprises contacting a hydrophobic chelator, a non-ionic detergent and metal ions so as to generate an aggregate comprising the hydrophobic chelator, the detergent and the metal ions; and contacting the aggregate with a medium comprising the antibody under conditions that allow partitioning of the antibody into the aggregate. Kits for isolating the antibody are also disclosed.
Type:
Application
Filed:
April 16, 2020
Publication date:
May 2, 2024
Applicants:
Ariel Scientific Innovations Ltd., Yeda Research and Development Co. Ltd.
Inventors:
Guy PATCHORNIK, Mordechai SHEVES, Irishi N. N. NAMBOOTHIRI, Gunasekaran DHANDAPANI